ATE142502T1 - Injizierbares arzneimittel zum schutz vor gewebebeschädigung durch ischemie - Google Patents

Injizierbares arzneimittel zum schutz vor gewebebeschädigung durch ischemie

Info

Publication number
ATE142502T1
ATE142502T1 AT92106213T AT92106213T ATE142502T1 AT E142502 T1 ATE142502 T1 AT E142502T1 AT 92106213 T AT92106213 T AT 92106213T AT 92106213 T AT92106213 T AT 92106213T AT E142502 T1 ATE142502 T1 AT E142502T1
Authority
AT
Austria
Prior art keywords
ischemia
damage caused
protect against
tissue damage
medicinal product
Prior art date
Application number
AT92106213T
Other languages
English (en)
Inventor
Robert L Hunter
Alexander Duncan
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/045,459 external-priority patent/US4801452A/en
Application filed by Univ Emory filed Critical Univ Emory
Application granted granted Critical
Publication of ATE142502T1 publication Critical patent/ATE142502T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Environmental Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT92106213T 1986-05-15 1987-05-08 Injizierbares arzneimittel zum schutz vor gewebebeschädigung durch ischemie ATE142502T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86358286A 1986-05-15 1986-05-15
US4388887A 1987-04-29 1987-04-29
US07/045,459 US4801452A (en) 1986-05-15 1987-05-07 Fibrinolytic composition

Publications (1)

Publication Number Publication Date
ATE142502T1 true ATE142502T1 (de) 1996-09-15

Family

ID=27366409

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92106213T ATE142502T1 (de) 1986-05-15 1987-05-08 Injizierbares arzneimittel zum schutz vor gewebebeschädigung durch ischemie

Country Status (11)

Country Link
EP (3) EP0266419B1 (de)
JP (9) JPH0610139B2 (de)
KR (1) KR880701107A (de)
AT (1) ATE142502T1 (de)
AU (1) AU599392B2 (de)
BR (1) BR8707308A (de)
DE (2) DE3789196T2 (de)
DK (1) DK10888A (de)
FI (1) FI94928C (de)
IL (1) IL82519A (de)
WO (1) WO1987006836A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8503097A (nl) * 1985-11-11 1987-06-01 Leuven Res & Dev Vzw Geneesmiddel met thrombolytische werking.
WO1987006836A1 (en) * 1986-05-15 1987-11-19 Emory University Fibrinolytic composition
US5039520A (en) * 1986-05-15 1991-08-13 Emory University Plasma extender
US4879109A (en) * 1986-05-15 1989-11-07 Emory University Method for treating burns
US5648071A (en) * 1986-05-15 1997-07-15 Emory University Method of treating tumors
US5182106A (en) * 1986-05-15 1993-01-26 Emory University Method for treating hypothermia
US5811088A (en) * 1987-02-20 1998-09-22 Emory University Antiinfective compounds and methods of use
US5372812A (en) * 1988-04-04 1994-12-13 The General Hospital Corporation Composition and method for acceleration of clot lysis
US5582862A (en) * 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
WO1989009817A1 (en) * 1988-04-04 1989-10-19 The General Hospital Corporation Composition and method for acceleration of clot lysis
EP0472657B1 (de) * 1989-05-17 1996-03-13 Research Corporation Technologies, Inc. Verfahren und zusammensetzung zur thrombosebehandlung beim säugetier
US7202225B1 (en) 1993-10-15 2007-04-10 Emanuele R Martin Therapeutic delivery compositions and methods of use thereof
US6933286B2 (en) 1991-03-19 2005-08-23 R. Martin Emanuele Therapeutic delivery compositions and methods of use thereof
CN1069741A (zh) 1991-03-19 1993-03-10 西特克斯公司 具有改进的生物活性的聚氧丙烯/聚氧乙烯共聚物
US5696298A (en) * 1991-03-19 1997-12-09 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
USRE38558E1 (en) 1991-03-19 2004-07-20 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
US5470568A (en) * 1992-02-13 1995-11-28 Arch Development Corporation Methods and compositions of a polymer (poloxamer) for cell repair
US5605687A (en) * 1992-05-15 1997-02-25 Arch Development Corporation Methods and compositions of a polymer (poloxamer) for repair of electrical injury
US5646203A (en) * 1994-03-31 1997-07-08 Toppan Moore Co., Ltd. Microcapsule-containing oil-based coating liquid, ink, coated sheet, and method of preparing the same
EP0803255A4 (de) * 1994-06-03 1999-06-30 Tsumura & Co Arzneimittel
KR100241202B1 (ko) * 1995-09-12 2000-02-01 니시무로 타이죠 전류미러회로
WO1998012334A2 (en) * 1996-09-20 1998-03-26 The General Hospital Corporation Chimeric, humanized and single chain antibodies to alpha-2-antiplasmin
US6969515B2 (en) 1999-11-13 2005-11-29 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US7544500B2 (en) 1999-11-13 2009-06-09 Talecris Biotherapeutics, Inc. Process for the production of a reversibly inactive acidified plasmin composition
US6355243B1 (en) 1999-11-13 2002-03-12 Bayer Corporation Method of thrombolysis by local delivery of active plasmin
US6964764B2 (en) 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
JP2004507473A (ja) * 2000-08-25 2004-03-11 オルガン　リカヴァリー　システムス　インコーポレイテッド 血栓溶解性器官処理および修復法
DE10314083A1 (de) * 2003-03-28 2004-10-14 Mcs Micro Carrier Systems Gmbh Produkt zum Schutz von Blutgefäßen
JPWO2006035673A1 (ja) * 2004-09-28 2008-05-15 独立行政法人科学技術振興機構 虚血性心臓傷害の新保護法
US8211817B2 (en) 2006-09-11 2012-07-03 Tosoh Corporation Fused silica glass and process for producing the same
US9877474B2 (en) 2012-09-08 2018-01-30 Organ Technologies, Inc. Method for maintaining organ or tissue for transplantation use for long period
KR102525493B1 (ko) * 2014-07-07 2023-04-25 라이프래프트 바이오사이언시즈 인코포레이티드 장기 순환 물질이 없는 폴록사머 조성물 및 이의 제조 방법 및 용도
GB201511207D0 (en) 2015-06-25 2015-08-12 Xvivo Perfusion Ab Isolated organ evaluation and treatment
US20190104718A1 (en) * 2017-10-09 2019-04-11 Efran Cano Entry barrier

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3641240A (en) * 1968-09-27 1972-02-08 Wyandotte Chemicals Corp Method for the treatment of an embolus or thrombus
US3980772A (en) * 1969-12-02 1976-09-14 Baxter Laboratories, Inc. Methods of dissolving blood clots and the like with streptokinase chemically bonded to a carbohydrate matrix
US3956259A (en) * 1973-01-30 1976-05-11 Baxter Laboratories, Inc. Fractionation of blood using block copolymer of ethylene oxide and polyoxypropylene polymer to recover fraction suitable for organ perfusate
US4186253A (en) * 1978-10-10 1980-01-29 The Green Cross Corporation Perfusate for preserving organ to be transplanted and preserving method
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
JPS5959629A (ja) * 1982-09-27 1984-04-05 Nippon Chem Res Kk 効力持続性組成物
JPS61176532A (ja) * 1985-01-30 1986-08-08 Green Cross Corp:The プラスミノ−ゲンアクチベ−タ−前駆体の安定化方法
WO1987006836A1 (en) * 1986-05-15 1987-11-19 Emory University Fibrinolytic composition

Also Published As

Publication number Publication date
FI880163A0 (fi) 1988-01-14
JPH0616562A (ja) 1994-01-25
EP0266419A4 (de) 1989-03-15
JPH0616565A (ja) 1994-01-25
EP0498470A3 (en) 1993-03-03
JPH0735338B2 (ja) 1995-04-19
JPH0653685B2 (ja) 1994-07-20
JPH06100454A (ja) 1994-04-12
EP0451880A2 (de) 1991-10-16
DE3751907D1 (de) 1996-10-17
DK10888A (da) 1988-03-11
EP0498470A2 (de) 1992-08-12
JPH0616571A (ja) 1994-01-25
JPH01500592A (ja) 1989-03-01
EP0498470B1 (de) 1996-09-11
JPH0735337B2 (ja) 1995-04-19
JPH0648951A (ja) 1994-02-22
FI880163L (fi) 1988-01-14
EP0451880A3 (en) 1991-12-27
EP0266419B1 (de) 1994-03-02
FI94928C (fi) 1995-11-27
EP0266419A1 (de) 1988-05-11
JPH0624993A (ja) 1994-02-01
AU599392B2 (en) 1990-07-19
JPH0616567A (ja) 1994-01-25
JPH0640924A (ja) 1994-02-15
BR8707308A (pt) 1988-09-13
WO1987006836A1 (en) 1987-11-19
JPH0757730B2 (ja) 1995-06-21
DE3789196D1 (de) 1994-04-07
DE3789196T2 (de) 1994-06-16
JPH0610139B2 (ja) 1994-02-09
IL82519A (en) 1992-05-25
FI94928B (fi) 1995-08-15
DE3751907T2 (de) 1997-04-03
KR880701107A (ko) 1988-07-25
AU7484087A (en) 1987-12-01
JPH0735336B2 (ja) 1995-04-19
DK10888D0 (da) 1988-01-11

Similar Documents

Publication Publication Date Title
ATE142502T1 (de) Injizierbares arzneimittel zum schutz vor gewebebeschädigung durch ischemie
NO891082D0 (no) Fremgangsmaate for fremstilling av peptidforbindelser.
PT96289A (pt) Processamento para a preparacao de composicoes farmaceuticas para o trtamento de infeccoes virais
HUT67285A (en) Cyclic ureas and analogues and pharmaceutical compositions
DE69327330D1 (de) Verfahren zum bekämpfen der pneumocystis carinii pneumonie und dafür verwendbare verbindungen
FI921522A0 (fi) Pyrazolopyridinfoerening och foerfarande foer dess framstaellning.
PT892794E (pt) Prodrogas de n-hidroximetil-talidomida aciladas de efeito imunomodulador
ES8502114A1 (es) Un procedimiento para preparar una beta-lactama.
JPS5429400A (en) Polymer comprising polyalkylpiperidine and its use as stabilizers
OA09119A (fr) Nouveaux céphèmes et leur préparation.
GB1502873A (en) Pharmaceutical compositions with ulcer healing activity
SE7503952L (sv) Sett att framstella spasmolytiska foreningar.
FR2409996A1 (fr) 15-epi-prostacycline et analogues, utiles notamment comme agents antithrombotiques et thrombolytiques et leur procede de preparation
GB1424432A (en) Pharmaceutical compositions
GB1508338A (en) Pharmaceutical compositions
ATE190226T1 (de) Zusammensetzungen zum auslösen cytotoxischer t- lymphozyten gegen viren
AR040650A1 (es) Polipeptido t 1249 pegilado, inhibitorio de la infeccion por h.i.v.
IT1204778B (it) Formulazioni farmaceutiche iniettabili di principi attivi ad attivita' anestetica generale
ES348538A1 (es) Procedimiento para la obtencion de nuevas sales de noratro-pina n-sustituida.
GB1316333A (en) Pyrimidyl-ureas their preparation and use as immunosuppresants and anti-viral agents
IE34313L (en) 2-hydroxy-5-aminobenzamides
JPS5535069A (en) Tetrapeptide derivative
SE9003040L (sv) Analoger av cyklolinopeptid a och anvaendning daerav
GB976217A (en) Improvements in or relating to novel substituted phenothiazines
WO1990011292A3 (fr) Composes anesthesiques a duree d'action controlee et compositions pharmaceutiques les contenant

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee